107 results
8-K
EX-10.1
BGNE
BeiGene Ltd
20 Mar 24
Departure of Directors or Certain Officers
4:10pm
”) of BeiGene, Ltd. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high
8-K
EX-99.1
BGNE
BeiGene Ltd
15 Mar 24
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
4:52pm
therapy. Hypothyroidism resolved in 27% of the 132 patients. The majority (86%) of patients with hypothyroidism required long-term thyroid hormone
8-K
EX-99.1
3gkoslnm1fec
9 Nov 23
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
4:08pm
8-K
EX-99.1
9mdov60d wh5
2 Aug 23
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
6:13am
8-K
EX-99.1
nupheoe i3
15 Jun 23
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
4:43pm
8-K
EX-99.2
tj3 ftydenzwni1uylz2
15 Jun 23
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
4:43pm
8-K
EX-10.1
mblirwrd
29 Mar 23
Other Events
4:03pm
8-K
EX-99.1
e3rkfqtdba0
22 Nov 22
Other Events
4:07pm
8-K
EX-99.1
jyiop hly
9 Nov 22
BeiGene Reports Third Quarter 2022 Financial Results
7:06am